nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—Imiquimod—skin cancer	0.126	0.292	CbGbCtD
Pimecrolimus—CYP3A4—Temozolomide—skin cancer	0.126	0.292	CbGbCtD
Pimecrolimus—CYP3A4—Vismodegib—skin cancer	0.0872	0.202	CbGbCtD
Pimecrolimus—CYP3A4—Vemurafenib—skin cancer	0.069	0.16	CbGbCtD
Pimecrolimus—CYP3A4—Docetaxel—skin cancer	0.0237	0.0548	CbGbCtD
Pimecrolimus—MTOR—leg—skin cancer	0.0198	0.133	CbGeAlD
Pimecrolimus—MTOR—forelimb—skin cancer	0.0196	0.132	CbGeAlD
Pimecrolimus—MTOR—hindlimb—skin cancer	0.0176	0.119	CbGeAlD
Pimecrolimus—MTOR—appendage—skin cancer	0.0151	0.102	CbGeAlD
Pimecrolimus—MTOR—blood vessel—skin cancer	0.00843	0.0567	CbGeAlD
Pimecrolimus—MTOR—neck—skin cancer	0.00603	0.0406	CbGeAlD
Pimecrolimus—FKBP1A—nipple—skin cancer	0.00548	0.0369	CbGeAlD
Pimecrolimus—FKBP1A—neck—skin cancer	0.00542	0.0365	CbGeAlD
Pimecrolimus—MTOR—connective tissue—skin cancer	0.00432	0.0291	CbGeAlD
Pimecrolimus—MTOR—epithelium—skin cancer	0.0041	0.0276	CbGeAlD
Pimecrolimus—MTOR—skin of body—skin cancer	0.0039	0.0263	CbGeAlD
Pimecrolimus—FKBP1A—connective tissue—skin cancer	0.00389	0.0262	CbGeAlD
Pimecrolimus—FKBP1A—epithelium—skin cancer	0.00369	0.0248	CbGeAlD
Pimecrolimus—MTOR—mammalian vulva—skin cancer	0.00356	0.0239	CbGeAlD
Pimecrolimus—FKBP1A—skin of body—skin cancer	0.00351	0.0236	CbGeAlD
Pimecrolimus—FKBP1A—mammalian vulva—skin cancer	0.0032	0.0215	CbGeAlD
Pimecrolimus—MTOR—lymphoid tissue—skin cancer	0.00316	0.0213	CbGeAlD
Pimecrolimus—MTOR—female reproductive system—skin cancer	0.00305	0.0205	CbGeAlD
Pimecrolimus—FKBP1A—lymphoid tissue—skin cancer	0.00284	0.0191	CbGeAlD
Pimecrolimus—FKBP1A—female reproductive system—skin cancer	0.00274	0.0184	CbGeAlD
Pimecrolimus—MTOR—head—skin cancer	0.00255	0.0171	CbGeAlD
Pimecrolimus—FKBP1A—head—skin cancer	0.00229	0.0154	CbGeAlD
Pimecrolimus—MTOR—lymph node—skin cancer	0.00178	0.012	CbGeAlD
Pimecrolimus—FKBP1A—lymph node—skin cancer	0.0016	0.0108	CbGeAlD
Pimecrolimus—Herpes simplex—Temozolomide—skin cancer	0.00121	0.00342	CcSEcCtD
Pimecrolimus—Eye irritation—Fluorouracil—skin cancer	0.0012	0.0034	CcSEcCtD
Pimecrolimus—Influenza—Imiquimod—skin cancer	0.00117	0.0033	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00115	0.00325	CcSEcCtD
Pimecrolimus—Bronchitis—Imiquimod—skin cancer	0.00112	0.00318	CcSEcCtD
Pimecrolimus—Herpes simplex—Fluorouracil—skin cancer	0.00112	0.00315	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Vismodegib—skin cancer	0.00109	0.00308	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Imiquimod—skin cancer	0.00109	0.00307	CcSEcCtD
Pimecrolimus—Influenza like illness—Temozolomide—skin cancer	0.00108	0.00306	CcSEcCtD
Pimecrolimus—Pain—Vismodegib—skin cancer	0.00108	0.00305	CcSEcCtD
Pimecrolimus—Constipation—Vismodegib—skin cancer	0.00108	0.00305	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Imiquimod—skin cancer	0.00107	0.00301	CcSEcCtD
Pimecrolimus—Skin exfoliation—Temozolomide—skin cancer	0.00107	0.00301	CcSEcCtD
Pimecrolimus—Infestation NOS—Imiquimod—skin cancer	0.00104	0.00294	CcSEcCtD
Pimecrolimus—Infestation—Imiquimod—skin cancer	0.00104	0.00294	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Vismodegib—skin cancer	0.00103	0.00291	CcSEcCtD
Pimecrolimus—Throat sore—Docetaxel—skin cancer	0.00103	0.00291	CcSEcCtD
Pimecrolimus—Eye disorder—Vemurafenib—skin cancer	0.00103	0.0029	CcSEcCtD
Pimecrolimus—Oropharyngeal discomfort—Docetaxel—skin cancer	0.00102	0.00288	CcSEcCtD
Pimecrolimus—Conjunctivitis—Imiquimod—skin cancer	0.00101	0.00286	CcSEcCtD
Pimecrolimus—Abdominal pain—Vismodegib—skin cancer	0.000997	0.00282	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Vemurafenib—skin cancer	0.000989	0.00279	CcSEcCtD
Pimecrolimus—Sinusitis—Imiquimod—skin cancer	0.000978	0.00276	CcSEcCtD
Pimecrolimus—Malnutrition—Vemurafenib—skin cancer	0.000955	0.0027	CcSEcCtD
Pimecrolimus—Erythema—Vemurafenib—skin cancer	0.000955	0.0027	CcSEcCtD
Pimecrolimus—Otitis media—Docetaxel—skin cancer	0.000954	0.00269	CcSEcCtD
Pimecrolimus—Ear pain—Temozolomide—skin cancer	0.00095	0.00268	CcSEcCtD
Pimecrolimus—Rhinitis—Imiquimod—skin cancer	0.000938	0.00265	CcSEcCtD
Pimecrolimus—Pharyngitis—Imiquimod—skin cancer	0.000929	0.00262	CcSEcCtD
Pimecrolimus—Back pain—Vemurafenib—skin cancer	0.000924	0.00261	CcSEcCtD
Pimecrolimus—Rhinorrhoea—Docetaxel—skin cancer	0.000917	0.00259	CcSEcCtD
Pimecrolimus—Gastroenteritis—Temozolomide—skin cancer	0.000915	0.00258	CcSEcCtD
Pimecrolimus—CYP3A4—female reproductive system—skin cancer	0.000895	0.00603	CbGeAlD
Pimecrolimus—Pruritus—Vismodegib—skin cancer	0.000893	0.00252	CcSEcCtD
Pimecrolimus—Nasal congestion—Temozolomide—skin cancer	0.00089	0.00251	CcSEcCtD
Pimecrolimus—Eye disorder—Imiquimod—skin cancer	0.000874	0.00247	CcSEcCtD
Pimecrolimus—Eye irritation—Docetaxel—skin cancer	0.00087	0.00246	CcSEcCtD
Pimecrolimus—Flushing—Imiquimod—skin cancer	0.000868	0.00245	CcSEcCtD
Pimecrolimus—Diarrhoea—Vismodegib—skin cancer	0.000863	0.00244	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Temozolomide—skin cancer	0.000859	0.00243	CcSEcCtD
Pimecrolimus—Swelling—Fluorouracil—skin cancer	0.000847	0.00239	CcSEcCtD
Pimecrolimus—Immune system disorder—Imiquimod—skin cancer	0.000845	0.00239	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Imiquimod—skin cancer	0.000843	0.00238	CcSEcCtD
Pimecrolimus—Cough—Vemurafenib—skin cancer	0.000833	0.00235	CcSEcCtD
Pimecrolimus—Bone disorder—Docetaxel—skin cancer	0.000822	0.00232	CcSEcCtD
Pimecrolimus—Oropharyngeal pain—Docetaxel—skin cancer	0.000817	0.00231	CcSEcCtD
Pimecrolimus—Malnutrition—Imiquimod—skin cancer	0.000815	0.0023	CcSEcCtD
Pimecrolimus—Erythema—Imiquimod—skin cancer	0.000815	0.0023	CcSEcCtD
Pimecrolimus—Arthralgia—Vemurafenib—skin cancer	0.000813	0.0023	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000808	0.00228	CcSEcCtD
Pimecrolimus—Vomiting—Vismodegib—skin cancer	0.000802	0.00227	CcSEcCtD
Pimecrolimus—Rash—Vismodegib—skin cancer	0.000796	0.00225	CcSEcCtD
Pimecrolimus—Dermatitis—Vismodegib—skin cancer	0.000795	0.00225	CcSEcCtD
Pimecrolimus—Back pain—Imiquimod—skin cancer	0.000788	0.00223	CcSEcCtD
Pimecrolimus—Face oedema—Temozolomide—skin cancer	0.000783	0.00221	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Vemurafenib—skin cancer	0.00078	0.0022	CcSEcCtD
Pimecrolimus—Infection—Vemurafenib—skin cancer	0.000774	0.00219	CcSEcCtD
Pimecrolimus—Nervous system disorder—Vemurafenib—skin cancer	0.000764	0.00216	CcSEcCtD
Pimecrolimus—Skin disorder—Vemurafenib—skin cancer	0.000757	0.00214	CcSEcCtD
Pimecrolimus—Nausea—Vismodegib—skin cancer	0.000749	0.00212	CcSEcCtD
Pimecrolimus—Pneumonia—Bleomycin—skin cancer	0.000745	0.0021	CcSEcCtD
Pimecrolimus—Angioedema—Imiquimod—skin cancer	0.000744	0.0021	CcSEcCtD
Pimecrolimus—Breast disorder—Temozolomide—skin cancer	0.000732	0.00207	CcSEcCtD
Pimecrolimus—Influenza like illness—Docetaxel—skin cancer	0.000721	0.00204	CcSEcCtD
Pimecrolimus—Cough—Imiquimod—skin cancer	0.000711	0.00201	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00071	0.00201	CcSEcCtD
Pimecrolimus—Skin exfoliation—Docetaxel—skin cancer	0.000709	0.002	CcSEcCtD
Pimecrolimus—Pneumonia—Dactinomycin—skin cancer	0.000695	0.00196	CcSEcCtD
Pimecrolimus—Arthralgia—Imiquimod—skin cancer	0.000693	0.00196	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000689	0.00195	CcSEcCtD
Pimecrolimus—Bronchitis—Temozolomide—skin cancer	0.000674	0.0019	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000673	0.0019	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Fluorouracil—skin cancer	0.000668	0.00189	CcSEcCtD
Pimecrolimus—Constipation—Vemurafenib—skin cancer	0.000667	0.00188	CcSEcCtD
Pimecrolimus—Oedema—Imiquimod—skin cancer	0.000665	0.00188	CcSEcCtD
Pimecrolimus—Infection—Imiquimod—skin cancer	0.00066	0.00187	CcSEcCtD
Pimecrolimus—Nervous system disorder—Imiquimod—skin cancer	0.000652	0.00184	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Temozolomide—skin cancer	0.000651	0.00184	CcSEcCtD
Pimecrolimus—Skin disorder—Imiquimod—skin cancer	0.000646	0.00182	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Temozolomide—skin cancer	0.000639	0.00181	CcSEcCtD
Pimecrolimus—Pneumonia—Temozolomide—skin cancer	0.000628	0.00177	CcSEcCtD
Pimecrolimus—Infestation NOS—Temozolomide—skin cancer	0.000625	0.00176	CcSEcCtD
Pimecrolimus—Infestation—Temozolomide—skin cancer	0.000625	0.00176	CcSEcCtD
Pimecrolimus—Flushing—Bleomycin—skin cancer	0.000617	0.00174	CcSEcCtD
Pimecrolimus—Body temperature increased—Vemurafenib—skin cancer	0.000616	0.00174	CcSEcCtD
Pimecrolimus—Pharyngitis—Dactinomycin—skin cancer	0.000615	0.00174	CcSEcCtD
Pimecrolimus—Swelling—Docetaxel—skin cancer	0.000611	0.00173	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000606	0.00171	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Fluorouracil—skin cancer	0.0006	0.00169	CcSEcCtD
Pimecrolimus—Paraesthesia—Imiquimod—skin cancer	0.000597	0.00169	CcSEcCtD
Pimecrolimus—Dyspnoea—Imiquimod—skin cancer	0.000593	0.00167	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Fluorouracil—skin cancer	0.000589	0.00166	CcSEcCtD
Pimecrolimus—Sinusitis—Temozolomide—skin cancer	0.000586	0.00166	CcSEcCtD
Pimecrolimus—Pneumonia—Fluorouracil—skin cancer	0.000579	0.00164	CcSEcCtD
Pimecrolimus—Erythema—Bleomycin—skin cancer	0.000579	0.00163	CcSEcCtD
Pimecrolimus—Infestation NOS—Fluorouracil—skin cancer	0.000576	0.00163	CcSEcCtD
Pimecrolimus—Infestation—Fluorouracil—skin cancer	0.000576	0.00163	CcSEcCtD
Pimecrolimus—Flushing—Dactinomycin—skin cancer	0.000575	0.00163	CcSEcCtD
Pimecrolimus—Hypersensitivity—Vemurafenib—skin cancer	0.000574	0.00162	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Imiquimod—skin cancer	0.000574	0.00162	CcSEcCtD
Pimecrolimus—Pain—Imiquimod—skin cancer	0.000568	0.00161	CcSEcCtD
Pimecrolimus—Conjunctivitis—Fluorouracil—skin cancer	0.000559	0.00158	CcSEcCtD
Pimecrolimus—Pharyngitis—Temozolomide—skin cancer	0.000557	0.00157	CcSEcCtD
Pimecrolimus—Pruritus—Vemurafenib—skin cancer	0.000552	0.00156	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Imiquimod—skin cancer	0.000544	0.00154	CcSEcCtD
Pimecrolimus—Epistaxis—Fluorouracil—skin cancer	0.000543	0.00153	CcSEcCtD
Pimecrolimus—Sinusitis—Fluorouracil—skin cancer	0.00054	0.00153	CcSEcCtD
Pimecrolimus—Erythema—Dactinomycin—skin cancer	0.00054	0.00152	CcSEcCtD
Pimecrolimus—Diarrhoea—Vemurafenib—skin cancer	0.000533	0.00151	CcSEcCtD
Pimecrolimus—Urticaria—Imiquimod—skin cancer	0.000528	0.00149	CcSEcCtD
Pimecrolimus—Body temperature increased—Imiquimod—skin cancer	0.000526	0.00148	CcSEcCtD
Pimecrolimus—Abdominal pain—Imiquimod—skin cancer	0.000526	0.00148	CcSEcCtD
Pimecrolimus—Eye disorder—Temozolomide—skin cancer	0.000524	0.00148	CcSEcCtD
Pimecrolimus—Flushing—Temozolomide—skin cancer	0.00052	0.00147	CcSEcCtD
Pimecrolimus—Rhinitis—Fluorouracil—skin cancer	0.000518	0.00146	CcSEcCtD
Pimecrolimus—Pharyngitis—Fluorouracil—skin cancer	0.000513	0.00145	CcSEcCtD
Pimecrolimus—Immune system disorder—Temozolomide—skin cancer	0.000506	0.00143	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Temozolomide—skin cancer	0.000505	0.00143	CcSEcCtD
Pimecrolimus—Cough—Bleomycin—skin cancer	0.000505	0.00143	CcSEcCtD
Pimecrolimus—Vomiting—Vemurafenib—skin cancer	0.000496	0.0014	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Docetaxel—skin cancer	0.000492	0.00139	CcSEcCtD
Pimecrolimus—Rash—Vemurafenib—skin cancer	0.000492	0.00139	CcSEcCtD
Pimecrolimus—Dermatitis—Vemurafenib—skin cancer	0.000491	0.00139	CcSEcCtD
Pimecrolimus—Hypersensitivity—Imiquimod—skin cancer	0.00049	0.00138	CcSEcCtD
Pimecrolimus—Headache—Vemurafenib—skin cancer	0.000488	0.00138	CcSEcCtD
Pimecrolimus—Malnutrition—Temozolomide—skin cancer	0.000488	0.00138	CcSEcCtD
Pimecrolimus—Erythema—Temozolomide—skin cancer	0.000488	0.00138	CcSEcCtD
Pimecrolimus—Breast disorder—Docetaxel—skin cancer	0.000487	0.00138	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Docetaxel—skin cancer	0.000482	0.00136	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Bleomycin—skin cancer	0.000472	0.00133	CcSEcCtD
Pimecrolimus—Oedema—Bleomycin—skin cancer	0.000472	0.00133	CcSEcCtD
Pimecrolimus—Back pain—Temozolomide—skin cancer	0.000472	0.00133	CcSEcCtD
Pimecrolimus—Pruritus—Imiquimod—skin cancer	0.00047	0.00133	CcSEcCtD
Pimecrolimus—Infection—Bleomycin—skin cancer	0.000469	0.00133	CcSEcCtD
Pimecrolimus—Nausea—Vemurafenib—skin cancer	0.000463	0.00131	CcSEcCtD
Pimecrolimus—Diarrhoea—Imiquimod—skin cancer	0.000455	0.00128	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR—FOXO4—skin cancer	0.000451	0.00684	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—FOXO4—skin cancer	0.000451	0.00684	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB2/ErbB3 signaling events—NRAS—skin cancer	0.00045	0.00683	CbGpPWpGaD
Pimecrolimus—Erythema—Fluorouracil—skin cancer	0.00045	0.00127	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB2—FOXO4—skin cancer	0.000449	0.00681	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—FOXO4—skin cancer	0.000446	0.00678	CbGpPWpGaD
Pimecrolimus—Angioedema—Temozolomide—skin cancer	0.000446	0.00126	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—PTGS2—skin cancer	0.000441	0.0067	CbGpPWpGaD
Pimecrolimus—Oedema—Dactinomycin—skin cancer	0.00044	0.00124	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FOXO4—skin cancer	0.00044	0.00668	CbGpPWpGaD
Pimecrolimus—Infection—Dactinomycin—skin cancer	0.000438	0.00124	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00043	0.00122	CcSEcCtD
Pimecrolimus—Cough—Temozolomide—skin cancer	0.000426	0.0012	CcSEcCtD
Pimecrolimus—Paraesthesia—Bleomycin—skin cancer	0.000424	0.0012	CcSEcCtD
Pimecrolimus—Vomiting—Imiquimod—skin cancer	0.000423	0.00119	CcSEcCtD
Pimecrolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—HRAS—skin cancer	0.000422	0.00641	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Bleomycin—skin cancer	0.000421	0.00119	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.00042	0.00638	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—FOXO4—skin cancer	0.00042	0.00638	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FOXO4—skin cancer	0.00042	0.00638	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—FOXO4—skin cancer	0.00042	0.00638	CbGpPWpGaD
Pimecrolimus—Rash—Imiquimod—skin cancer	0.000419	0.00118	CcSEcCtD
Pimecrolimus—Dermatitis—Imiquimod—skin cancer	0.000419	0.00118	CcSEcCtD
Pimecrolimus—Pneumonia—Docetaxel—skin cancer	0.000418	0.00118	CcSEcCtD
Pimecrolimus—Headache—Imiquimod—skin cancer	0.000416	0.00118	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—FOXO4—skin cancer	0.000416	0.00632	CbGpPWpGaD
Pimecrolimus—Arthralgia—Temozolomide—skin cancer	0.000416	0.00117	CcSEcCtD
Pimecrolimus—Infestation—Docetaxel—skin cancer	0.000415	0.00117	CcSEcCtD
Pimecrolimus—Infestation NOS—Docetaxel—skin cancer	0.000415	0.00117	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000413	0.00117	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—FOXO4—skin cancer	0.000412	0.00626	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR3-mediated signaling events—KRAS—skin cancer	0.000411	0.00625	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—FOXO4—skin cancer	0.000411	0.00624	CbGpPWpGaD
Pimecrolimus—Pain—Bleomycin—skin cancer	0.000404	0.00114	CcSEcCtD
Pimecrolimus—Conjunctivitis—Docetaxel—skin cancer	0.000404	0.00114	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000401	0.00113	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Temozolomide—skin cancer	0.000398	0.00113	CcSEcCtD
Pimecrolimus—Oedema—Temozolomide—skin cancer	0.000398	0.00113	CcSEcCtD
Pimecrolimus—Infection—Temozolomide—skin cancer	0.000396	0.00112	CcSEcCtD
Pimecrolimus—Nausea—Imiquimod—skin cancer	0.000395	0.00112	CcSEcCtD
Pimecrolimus—Epistaxis—Docetaxel—skin cancer	0.000392	0.00111	CcSEcCtD
Pimecrolimus—MTOR—Alpha 6 Beta 4 signaling pathway—HRAS—skin cancer	0.000391	0.00594	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Temozolomide—skin cancer	0.000391	0.0011	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—FOXO4—skin cancer	0.000389	0.0059	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB2/ErbB3 signaling events—KRAS—skin cancer	0.000387	0.00588	CbGpPWpGaD
Pimecrolimus—Skin disorder—Temozolomide—skin cancer	0.000387	0.00109	CcSEcCtD
Pimecrolimus—Pain—Dactinomycin—skin cancer	0.000377	0.00106	CcSEcCtD
Pimecrolimus—Urticaria—Bleomycin—skin cancer	0.000375	0.00106	CcSEcCtD
Pimecrolimus—Rhinitis—Docetaxel—skin cancer	0.000374	0.00106	CcSEcCtD
Pimecrolimus—Body temperature increased—Bleomycin—skin cancer	0.000373	0.00105	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FOXO4—skin cancer	0.000372	0.00565	CbGpPWpGaD
Pimecrolimus—Pharyngitis—Docetaxel—skin cancer	0.00037	0.00105	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Fluorouracil—skin cancer	0.000367	0.00104	CcSEcCtD
Pimecrolimus—Oedema—Fluorouracil—skin cancer	0.000367	0.00104	CcSEcCtD
Pimecrolimus—Infection—Fluorouracil—skin cancer	0.000365	0.00103	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000363	0.00103	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Dactinomycin—skin cancer	0.00036	0.00102	CcSEcCtD
Pimecrolimus—Nervous system disorder—Fluorouracil—skin cancer	0.00036	0.00102	CcSEcCtD
Pimecrolimus—Paraesthesia—Temozolomide—skin cancer	0.000358	0.00101	CcSEcCtD
Pimecrolimus—Dyspnoea—Temozolomide—skin cancer	0.000355	0.001	CcSEcCtD
Pimecrolimus—MTOR—CXCR3-mediated signaling events—HRAS—skin cancer	0.00035	0.00531	CbGpPWpGaD
Pimecrolimus—Eye disorder—Docetaxel—skin cancer	0.000348	0.000984	CcSEcCtD
Pimecrolimus—Abdominal pain—Dactinomycin—skin cancer	0.000348	0.000984	CcSEcCtD
Pimecrolimus—Body temperature increased—Dactinomycin—skin cancer	0.000348	0.000984	CcSEcCtD
Pimecrolimus—Hypersensitivity—Bleomycin—skin cancer	0.000348	0.000983	CcSEcCtD
Pimecrolimus—Flushing—Docetaxel—skin cancer	0.000346	0.000978	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Temozolomide—skin cancer	0.000344	0.000972	CcSEcCtD
Pimecrolimus—Constipation—Temozolomide—skin cancer	0.000341	0.000962	CcSEcCtD
Pimecrolimus—Pain—Temozolomide—skin cancer	0.000341	0.000962	CcSEcCtD
Pimecrolimus—MTOR—ErbB1 downstream signaling—BRAF—skin cancer	0.000337	0.00512	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—BRAF—skin cancer	0.000337	0.00512	CbGpPWpGaD
Pimecrolimus—Immune system disorder—Docetaxel—skin cancer	0.000337	0.000952	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Docetaxel—skin cancer	0.000336	0.000949	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000334	0.000945	CcSEcCtD
Pimecrolimus—Pruritus—Bleomycin—skin cancer	0.000334	0.000944	CcSEcCtD
Pimecrolimus—MTOR—LKB1 signaling events—TP53—skin cancer	0.000331	0.00503	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Fluorouracil—skin cancer	0.00033	0.000931	CcSEcCtD
Pimecrolimus—MTOR—ErbB2/ErbB3 signaling events—HRAS—skin cancer	0.000329	0.005	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Fluorouracil—skin cancer	0.000327	0.000924	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Temozolomide—skin cancer	0.000326	0.00092	CcSEcCtD
Pimecrolimus—Erythema—Docetaxel—skin cancer	0.000325	0.000917	CcSEcCtD
Pimecrolimus—Malnutrition—Docetaxel—skin cancer	0.000325	0.000917	CcSEcCtD
Pimecrolimus—Hypersensitivity—Dactinomycin—skin cancer	0.000325	0.000917	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000317	0.000895	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—TLR7—skin cancer	0.000317	0.00481	CbGpPWpGaD
Pimecrolimus—Urticaria—Temozolomide—skin cancer	0.000316	0.000894	CcSEcCtD
Pimecrolimus—Body temperature increased—Temozolomide—skin cancer	0.000315	0.00089	CcSEcCtD
Pimecrolimus—Abdominal pain—Temozolomide—skin cancer	0.000315	0.00089	CcSEcCtD
Pimecrolimus—Back pain—Docetaxel—skin cancer	0.000314	0.000887	CcSEcCtD
Pimecrolimus—Pain—Fluorouracil—skin cancer	0.000314	0.000887	CcSEcCtD
Pimecrolimus—MTOR—ErbB Signaling Pathway—KRAS—skin cancer	0.000311	0.00472	CbGpPWpGaD
Pimecrolimus—MTOR—mTOR signaling pathway—NRAS—skin cancer	0.000307	0.00467	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Dactinomycin—skin cancer	0.000301	0.000851	CcSEcCtD
Pimecrolimus—Vomiting—Bleomycin—skin cancer	0.0003	0.000848	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.0003	0.00456	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RHOU—skin cancer	0.0003	0.00455	CbGpPWpGaD
Pimecrolimus—Rash—Bleomycin—skin cancer	0.000298	0.000841	CcSEcCtD
Pimecrolimus—Dermatitis—Bleomycin—skin cancer	0.000298	0.00084	CcSEcCtD
Pimecrolimus—Hypersensitivity—Temozolomide—skin cancer	0.000294	0.000829	CcSEcCtD
Pimecrolimus—Urticaria—Fluorouracil—skin cancer	0.000292	0.000824	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—skin cancer	0.000291	0.00442	CbGpPWpGaD
Pimecrolimus—Body temperature increased—Fluorouracil—skin cancer	0.00029	0.00082	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—FOXO4—skin cancer	0.000286	0.00434	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—CDK4—skin cancer	0.000285	0.00433	CbGpPWpGaD
Pimecrolimus—Cough—Docetaxel—skin cancer	0.000283	0.0008	CcSEcCtD
Pimecrolimus—MTOR—TSLP Signaling Pathway—IL6—skin cancer	0.000282	0.00429	CbGpPWpGaD
Pimecrolimus—Pruritus—Temozolomide—skin cancer	0.000282	0.000796	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—CSPG4—skin cancer	0.000282	0.00427	CbGpPWpGaD
Pimecrolimus—Nausea—Bleomycin—skin cancer	0.000281	0.000792	CcSEcCtD
Pimecrolimus—Vomiting—Dactinomycin—skin cancer	0.00028	0.000791	CcSEcCtD
Pimecrolimus—Rash—Dactinomycin—skin cancer	0.000278	0.000785	CcSEcCtD
Pimecrolimus—Arthralgia—Docetaxel—skin cancer	0.000276	0.000781	CcSEcCtD
Pimecrolimus—MTOR—ErbB Signaling Pathway—TP53—skin cancer	0.000276	0.00419	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000274	0.000775	CcSEcCtD
Pimecrolimus—Diarrhoea—Temozolomide—skin cancer	0.000273	0.00077	CcSEcCtD
Pimecrolimus—Hypersensitivity—Fluorouracil—skin cancer	0.00027	0.000764	CcSEcCtD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—KRAS—skin cancer	0.000268	0.00407	CbGpPWpGaD
Pimecrolimus—Oedema—Docetaxel—skin cancer	0.000265	0.000748	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Docetaxel—skin cancer	0.000265	0.000748	CcSEcCtD
Pimecrolimus—MTOR—mTOR signaling pathway—KRAS—skin cancer	0.000265	0.00402	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—HRAS—skin cancer	0.000264	0.00401	CbGpPWpGaD
Pimecrolimus—Infection—Docetaxel—skin cancer	0.000263	0.000744	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TP53—skin cancer	0.000263	0.00399	CbGpPWpGaD
Pimecrolimus—Nausea—Dactinomycin—skin cancer	0.000262	0.000739	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—PTCH2—skin cancer	0.00026	0.00395	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Docetaxel—skin cancer	0.00026	0.000734	CcSEcCtD
Pimecrolimus—Pruritus—Fluorouracil—skin cancer	0.00026	0.000734	CcSEcCtD
Pimecrolimus—Skin disorder—Docetaxel—skin cancer	0.000257	0.000727	CcSEcCtD
Pimecrolimus—Vomiting—Temozolomide—skin cancer	0.000253	0.000716	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—BRAF—skin cancer	0.000252	0.00383	CbGpPWpGaD
Pimecrolimus—Rash—Temozolomide—skin cancer	0.000251	0.00071	CcSEcCtD
Pimecrolimus—Diarrhoea—Fluorouracil—skin cancer	0.000251	0.000709	CcSEcCtD
Pimecrolimus—MTOR—IRS-mediated signalling—NRAS—skin cancer	0.000251	0.00381	CbGpPWpGaD
Pimecrolimus—Dermatitis—Temozolomide—skin cancer	0.000251	0.000709	CcSEcCtD
Pimecrolimus—Headache—Temozolomide—skin cancer	0.00025	0.000705	CcSEcCtD
Pimecrolimus—MTOR—IRS-related events—NRAS—skin cancer	0.000244	0.00371	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—NRAS—skin cancer	0.000242	0.00367	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000241	0.000682	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL6—skin cancer	0.00024	0.00365	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—BRAF—skin cancer	0.000238	0.00362	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—BRAF—skin cancer	0.000238	0.00362	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—TP53—skin cancer	0.000238	0.00361	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Docetaxel—skin cancer	0.000238	0.000672	CcSEcCtD
Pimecrolimus—Nausea—Temozolomide—skin cancer	0.000237	0.000668	CcSEcCtD
Pimecrolimus—Dyspnoea—Docetaxel—skin cancer	0.000236	0.000667	CcSEcCtD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—NRAS—skin cancer	0.000236	0.00358	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—NRAS—skin cancer	0.000236	0.00358	CbGpPWpGaD
Pimecrolimus—Vomiting—Fluorouracil—skin cancer	0.000233	0.000659	CcSEcCtD
Pimecrolimus—Rash—Fluorouracil—skin cancer	0.000231	0.000654	CcSEcCtD
Pimecrolimus—Dermatitis—Fluorouracil—skin cancer	0.000231	0.000653	CcSEcCtD
Pimecrolimus—Headache—Fluorouracil—skin cancer	0.00023	0.00065	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Docetaxel—skin cancer	0.000229	0.000646	CcSEcCtD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—HRAS—skin cancer	0.000228	0.00346	CbGpPWpGaD
Pimecrolimus—MTOR—AMPK Signaling—TP53—skin cancer	0.000227	0.00344	CbGpPWpGaD
Pimecrolimus—Constipation—Docetaxel—skin cancer	0.000227	0.00064	CcSEcCtD
Pimecrolimus—Pain—Docetaxel—skin cancer	0.000227	0.00064	CcSEcCtD
Pimecrolimus—MTOR—TSH signaling pathway—HRAS—skin cancer	0.000225	0.00341	CbGpPWpGaD
Pimecrolimus—MTOR—mTOR signaling pathway—HRAS—skin cancer	0.000225	0.00341	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—BRAF—skin cancer	0.000222	0.00337	CbGpPWpGaD
Pimecrolimus—Nausea—Fluorouracil—skin cancer	0.000218	0.000616	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Docetaxel—skin cancer	0.000217	0.000612	CcSEcCtD
Pimecrolimus—MTOR—IRS-mediated signalling—KRAS—skin cancer	0.000216	0.00328	CbGpPWpGaD
Pimecrolimus—MTOR—CDC42 signaling events—HRAS—skin cancer	0.000214	0.00326	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—NRAS—skin cancer	0.000212	0.00322	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—KRAS—skin cancer	0.00021	0.00319	CbGpPWpGaD
Pimecrolimus—Abdominal pain—Docetaxel—skin cancer	0.000209	0.000592	CcSEcCtD
Pimecrolimus—Body temperature increased—Docetaxel—skin cancer	0.000209	0.000592	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—NRAS—skin cancer	0.000209	0.00317	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—KRAS—skin cancer	0.000208	0.00316	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—HRAS—skin cancer	0.000203	0.00308	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—KRAS—skin cancer	0.000203	0.00308	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—KRAS—skin cancer	0.000203	0.00308	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	0.000201	0.00305	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GLI2—skin cancer	0.000197	0.00299	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—NRAS—skin cancer	0.000197	0.00299	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—BRAF—skin cancer	0.000197	0.00299	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—NRAS—skin cancer	0.000196	0.00297	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Docetaxel—skin cancer	0.000195	0.000551	CcSEcCtD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—skin cancer	0.000193	0.00293	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SHH—skin cancer	0.000191	0.00291	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ENO2—skin cancer	0.000191	0.00291	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MC1R—skin cancer	0.000188	0.00286	CbGpPWpGaD
Pimecrolimus—Pruritus—Docetaxel—skin cancer	0.000187	0.00053	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—GLI1—skin cancer	0.000185	0.00281	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR7—skin cancer	0.000184	0.0028	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—HRAS—skin cancer	0.000184	0.00279	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—KRAS—skin cancer	0.000182	0.00277	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDK4—skin cancer	0.000182	0.00277	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Docetaxel—skin cancer	0.000181	0.000512	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—KRAS—skin cancer	0.00018	0.00273	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	0.000179	0.00271	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—HRAS—skin cancer	0.000179	0.00271	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—skin cancer	0.000177	0.00269	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—IL6—skin cancer	0.000176	0.00267	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SUFU—skin cancer	0.000176	0.00267	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—HRAS—skin cancer	0.000172	0.00262	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—HRAS—skin cancer	0.000172	0.00262	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—IL6—skin cancer	0.000171	0.0026	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—KRAS—skin cancer	0.00017	0.00258	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—skin cancer	0.000169	0.00257	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—KRAS—skin cancer	0.000168	0.00256	CbGpPWpGaD
Pimecrolimus—Vomiting—Docetaxel—skin cancer	0.000168	0.000476	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—NRAS—skin cancer	0.000167	0.00254	CbGpPWpGaD
Pimecrolimus—Rash—Docetaxel—skin cancer	0.000167	0.000472	CcSEcCtD
Pimecrolimus—Dermatitis—Docetaxel—skin cancer	0.000167	0.000471	CcSEcCtD
Pimecrolimus—Headache—Docetaxel—skin cancer	0.000166	0.000469	CcSEcCtD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—IL6—skin cancer	0.000165	0.0025	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—IL6—skin cancer	0.000165	0.0025	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FOXO4—skin cancer	0.000163	0.00248	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—skin cancer	0.000162	0.00246	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—NRAS—skin cancer	0.00016	0.00243	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CSPG4—skin cancer	0.000158	0.0024	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—NRAS—skin cancer	0.000158	0.00239	CbGpPWpGaD
Pimecrolimus—Nausea—Docetaxel—skin cancer	0.000157	0.000445	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—FOXO4—skin cancer	0.000157	0.00238	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FOXO4—skin cancer	0.000156	0.00237	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—skin cancer	0.000155	0.00235	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—HRAS—skin cancer	0.000155	0.00235	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	0.000153	0.00232	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—BRAF—skin cancer	0.000151	0.0023	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—NRAS—skin cancer	0.000151	0.00229	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—NRAS—skin cancer	0.00015	0.00228	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—NRAS—skin cancer	0.000149	0.00226	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—skin cancer	0.000148	0.00225	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—NRAS—skin cancer	0.000148	0.00225	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTCH2—skin cancer	0.000146	0.00222	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—skin cancer	0.000146	0.00222	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—skin cancer	0.000146	0.00222	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—HRAS—skin cancer	0.000144	0.00219	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—KRAS—skin cancer	0.000144	0.00219	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—HRAS—skin cancer	0.000143	0.00217	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—NRAS—skin cancer	0.00014	0.00212	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	0.00014	0.00212	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—NRAS—skin cancer	0.00014	0.00212	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN2A—skin cancer	0.000139	0.00212	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—NRAS—skin cancer	0.000138	0.0021	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—IL6—skin cancer	0.000138	0.0021	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—KRAS—skin cancer	0.000138	0.00209	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—NRAS—skin cancer	0.000137	0.00208	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—IL6—skin cancer	0.000137	0.00208	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—NRAS—skin cancer	0.000137	0.00207	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—skin cancer	0.000136	0.00207	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—KRAS—skin cancer	0.000136	0.00206	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SHH—skin cancer	0.000134	0.00203	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RASA1—skin cancer	0.000133	0.00202	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—KRAS—skin cancer	0.00013	0.00197	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—NRAS—skin cancer	0.000129	0.00196	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—KRAS—skin cancer	0.000129	0.00196	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—skin cancer	0.000129	0.00196	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—KRAS—skin cancer	0.000128	0.00195	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—KRAS—skin cancer	0.000128	0.00194	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTCH1—skin cancer	0.000127	0.00193	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SMO—skin cancer	0.000127	0.00193	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	0.000126	0.00191	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTGER4—skin cancer	0.000124	0.00188	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	0.000124	0.00188	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—HRAS—skin cancer	0.000122	0.00186	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—skin cancer	0.000121	0.00184	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—HRAS—skin cancer	0.00012	0.00183	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	0.00012	0.00182	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—KRAS—skin cancer	0.00012	0.00182	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—KRAS—skin cancer	0.00012	0.00182	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—KRAS—skin cancer	0.000119	0.00181	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—KRAS—skin cancer	0.000118	0.00179	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—KRAS—skin cancer	0.000117	0.00178	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—IL6—skin cancer	0.000117	0.00178	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—HRAS—skin cancer	0.000117	0.00178	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—HRAS—skin cancer	0.000115	0.00175	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—IL6—skin cancer	0.000112	0.0017	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—KRAS—skin cancer	0.000111	0.00169	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ERCC2—skin cancer	0.000111	0.00169	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GLI2—skin cancer	0.000111	0.00168	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—HRAS—skin cancer	0.000111	0.00168	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—IL6—skin cancer	0.00011	0.00168	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—HRAS—skin cancer	0.00011	0.00167	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—HRAS—skin cancer	0.00011	0.00166	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—skin cancer	0.00011	0.00166	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FOXO4—skin cancer	0.000109	0.00166	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—HRAS—skin cancer	0.000109	0.00166	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—HRAS—skin cancer	0.000109	0.00165	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SHH—skin cancer	0.000108	0.00163	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ENO2—skin cancer	0.000108	0.00163	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	0.000107	0.00162	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	0.000106	0.00162	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MC1R—skin cancer	0.000106	0.00161	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—IL6—skin cancer	0.000105	0.0016	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6—skin cancer	0.000105	0.00159	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6—skin cancer	0.000104	0.00159	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GLI1—skin cancer	0.000104	0.00158	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TERT—skin cancer	0.000104	0.00158	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IL6—skin cancer	0.000104	0.00158	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—HRAS—skin cancer	0.000102	0.00155	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	0.000102	0.00155	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—HRAS—skin cancer	0.000102	0.00155	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—HRAS—skin cancer	0.000101	0.00154	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—skin cancer	0.0001	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—HRAS—skin cancer	9.99e-05	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SUFU—skin cancer	9.88e-05	0.0015	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	9.77e-05	0.00148	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IL6—skin cancer	9.77e-05	0.00148	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6—skin cancer	9.77e-05	0.00148	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—IL6—skin cancer	9.69e-05	0.00147	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6—skin cancer	9.6e-05	0.00146	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6—skin cancer	9.56e-05	0.00145	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—NRAS—skin cancer	9.51e-05	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FOXO4—skin cancer	9.5e-05	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—HRAS—skin cancer	9.45e-05	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	9.04e-05	0.00137	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FOXO4—skin cancer	8.77e-05	0.00133	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	8.66e-05	0.00131	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—BRAF—skin cancer	8.25e-05	0.00125	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—KRAS—skin cancer	8.18e-05	0.00124	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—skin cancer	7.76e-05	0.00118	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SHH—skin cancer	7.54e-05	0.00114	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RASA1—skin cancer	7.49e-05	0.00114	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TERT—skin cancer	7.3e-05	0.00111	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTCH1—skin cancer	7.14e-05	0.00108	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SMO—skin cancer	7.14e-05	0.00108	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—skin cancer	7.1e-05	0.00108	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—HRAS—skin cancer	6.96e-05	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTGER4—skin cancer	6.96e-05	0.00106	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—skin cancer	6.67e-05	0.00101	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—skin cancer	6.66e-05	0.00101	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERCC2—skin cancer	6.25e-05	0.000949	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FOXO4—skin cancer	6.14e-05	0.000933	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TERT—skin cancer	5.86e-05	0.00089	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—BRAF—skin cancer	5.78e-05	0.000877	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NRAS—skin cancer	5.42e-05	0.000823	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NRAS—skin cancer	5.21e-05	0.000791	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NRAS—skin cancer	5.19e-05	0.000787	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KRAS—skin cancer	4.67e-05	0.000709	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—BRAF—skin cancer	4.64e-05	0.000705	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KRAS—skin cancer	4.48e-05	0.000681	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KRAS—skin cancer	4.46e-05	0.000678	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLIN2—skin cancer	4.36e-05	0.000662	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TERT—skin cancer	4.1e-05	0.000623	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HRAS—skin cancer	3.97e-05	0.000602	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HRAS—skin cancer	3.81e-05	0.000579	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—skin cancer	3.8e-05	0.000577	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HRAS—skin cancer	3.79e-05	0.000576	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—skin cancer	3.75e-05	0.000569	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NRAS—skin cancer	3.63e-05	0.000551	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—skin cancer	3.63e-05	0.000551	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CSPG4—skin cancer	3.52e-05	0.000534	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—BRAF—skin cancer	3.25e-05	0.000493	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NRAS—skin cancer	3.16e-05	0.00048	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KRAS—skin cancer	3.13e-05	0.000475	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NRAS—skin cancer	2.92e-05	0.000443	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—skin cancer	2.78e-05	0.000422	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KRAS—skin cancer	2.72e-05	0.000413	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HRAS—skin cancer	2.66e-05	0.000403	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—skin cancer	2.54e-05	0.000386	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KRAS—skin cancer	2.51e-05	0.000381	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ENO2—skin cancer	2.39e-05	0.000363	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HRAS—skin cancer	2.31e-05	0.000351	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—skin cancer	2.21e-05	0.000336	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HRAS—skin cancer	2.13e-05	0.000324	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NRAS—skin cancer	2.04e-05	0.00031	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—skin cancer	2.04e-05	0.00031	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KRAS—skin cancer	1.76e-05	0.000267	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—skin cancer	1.56e-05	0.000237	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRAS—skin cancer	1.49e-05	0.000227	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—skin cancer	1.43e-05	0.000217	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ERCC2—skin cancer	1.39e-05	0.000211	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—skin cancer	8.33e-06	0.000126	CbGpPWpGaD
